By 340B Matters 2020 was a difficult year for America’s healthcare first responders. But even during the worst health crisis of our lifetime, they never hesitated to put their own lives at risk to save others. With every new case they persevered, even as their workforce...
By 340B Matters Sometimes the best course of action is to do nothing. In the case of the 340B Drug Discount Program, the vast majority of pharmaceutical companies have chosen just that. These manufacturers deserve credit for doing the right thing. So far, six drug companies have decided...
By 340B Matters Now is the time to stand up for your state’s healthcare first responders and safety-net providers under direct assault from Big Pharma’s attacks on the 340B Drug Discount Program. Other state leaders have risen to the occasion in the midst of the pandemic. Twenty-nine...
By 340B Matters The best solution to a national problem occasionally surfaces far from Washington, DC. After months of overcharges to safety-net healthcare providers during a national pandemic, a top Florida Medicaid official has called out a key drug company in a letter that is likely...
By 340B Matters America is in the grip of a massive pandemic surge. As healthcare first-responders struggle with the onslaught of sick patients, Big Pharma continues to undercut the resources of safety-net hospitals and clinics. The situation is dire. As of December 1st there were 13.6 million...
By 340B Matters America’s healthcare first responders are girding for the looming winter surge in the pandemic. Amid the stress and strain, the 340B Drug Discount Program is a lifeline that helps safety-net providers care for underserved patients across the country. Congress designed the 340B program nearly...
By 340B Matters Senator Lamar Alexander (R-Tenn.) and Rep. Greg Walden (R-Ore.) have asked stakeholders in the 340B Drug Discount Program to submit ideas on how it can be improved. It’s a request that both pharmaceutical manufacturers and safety-net healthcare providers should take seriously. With a few updates, the...
By 340B Matters The drug industry and its surrogates have contended for years that the 340B Drug Discount Program somehow raises drug prices overall. It has argued that discounts provided under 340B to safety-net hospitals and clinics are offset by manufacturers when selling those same medicines at...
By 340B Matters The drug industry is spoiling for a legal fight over the 340B Drug Discount Program. Safety-net hospitals and clinics should give them one by suing over clear breaches of federal law. By turns peremptory and obnoxious, Eli Lilly, AztraZeneca, Merck and Sanofi have unilaterally...
By 340B Matters In response to Big Pharma’s recent unprecedented attacks on the 340B Drug Discount Program, Congress and the Department of Health and Human Services have put the manufacturers on notice that their actions may be formally rebuked by the federal government. HHS General Counsel Robert...
